BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 815434)

  • 1. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.
    Arroyave CM; Wilson MR; Tan EM
    J Immunol; 1976 Mar; 116(3):821-6. PubMed ID: 815434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the alternative complement pathway in systemic lupus erythematosus.
    Wilson MR; Arroyave CM; Nakamura RM; Vaughan JH; Tan EM
    Clin Exp Immunol; 1976 Oct; 26(1):11-20. PubMed ID: 826360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.
    Vallota EH; Götze O; Spiegelberg HL; Forristal J; West CD; Müller-Eberhard HJ
    J Exp Med; 1974 May; 139(5):1249-61. PubMed ID: 4207623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the alternative pathway of complement by antiserum to factor B.
    Wilson MR; Arroyave CM; Tan EM
    J Lab Clin Med; 1979 Mar; 93(3):493-8. PubMed ID: 107255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.
    Adu D; Williams DG
    Clin Exp Immunol; 1984 Mar; 55(3):495-501. PubMed ID: 6705265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
    Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
    J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
    Arnaout MA; Davis AE; Rosen RS; Alper CA
    J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
    Whaley K; Schur PH; Ruddy S
    Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
    Adam C; Williams DG; Peters DK
    Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement fixing properties of antibodies to double-stranded DNA in systemic lupus erythematosus.
    Gharavi AE; Elkon KB; Schifferli JA; Hughes GR
    J Clin Lab Immunol; 1981 Nov; 6(3):251-5. PubMed ID: 7338885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of low m.w., C3-bearing immunoglobulin in human serum.
    Jacobs RJ; Reichlin M
    J Immunol; 1983 Jun; 130(6):2775-81. PubMed ID: 6602181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation by circulating serum factors in human glomerulonephritis.
    Meri S
    Clin Exp Immunol; 1985 Feb; 59(2):276-84. PubMed ID: 3919977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
    Densen P; McRill CM; Ross SC
    J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
    Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
    Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the second component of complement (C2) by electroimmunoassay in sera from patients with systemic lupus erythematosus.
    Ueda A; Kusaba T; Yanase T
    Clin Exp Immunol; 1983 Jul; 53(1):217-24. PubMed ID: 6409476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K; Schur PH; Ruddy S
    J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of nephritic factor as an immunoglobulin.
    Williams DG; Bartlett A; Duffus P
    Clin Exp Immunol; 1978 Sep; 33(3):425-9. PubMed ID: 104814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.